Close this search box.
Close this search box.

March 25, 2022

Within3 in PharmExec: Better Insights Management

A Q&A with Within3 CEO Lance Hill about the insight gap challenge, and how industry leaders are solving it.
insight gap challenges

The way life science companies gather insight is changing. In PharmExec, Within3 CEO Lance Hill sits down for a Q&A to discuss the insight gap, the challenges of selecting key opinion leaders (KOLs), how insight blind spots ripple across the product development process, and the challenge of increasing diversity and inclusion in pharma.

“For life science companies, an insight is a key market signal that allows them to better understand their disease community – including the health care professionals and the patients they serve. Insights can be gained from a wide range of sources, whether it be a payer, patient, or healthcare professional,” says Hill. “Without insights, and more importantly, the wider context around those insights, pharma companies are flying blind with their business strategy.

Hill describes how COVID-19 placed increased pressure on drug development and clinical trial execution in two ways: by creating an urgent need for new medicines and pausing or slowing down other research. “Against the backdrop of historic difficulty in taking drugs to market in a complex post-COVID landscape, life science organizations need the right insights to make the right decisions.”

To learn more about the insight gap challenge for pharmaceutical and medical device companies and how industry leaders are solving it with better insights management, read the article.

Related Posts:

Modern insights management

Within3 on MAPS: Modern Insights Management

virtual engagement for medical affairs

Within3 in MedCityNews: Digital collaboration here to stay for Pfizer, Merck, others

AI applications

Within3 in European Pharmaceutical Manufacturer: how AI is changing the way pharma companies work

More insights, direct to your inbox.